Leapfrog Bio is a clinical-stage precision oncology company accelerating cancer drug development by identifying clinical-stage molecules that can be retargeted as directed therapies for cancers with undruggable driver mutations. The company’s lead program is a Phase 2 proof-of-concept trial evaluating a small molecule in three solid cancers with an unaddressed, but frequent, loss-of-function genetic mutation. The company’s Precision PGx Platform provides a repeatable and scalable in vitro system to identify existing small-molecule drugs that can be developed to treat cancers driven by loss-of-function mutations with a high probability of clinical success.
Company Details
- Employees
- 10
- Founded
- 2019
- Address
- 400 Oyster Point Blvd, Suite 203,canada
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.leapfrog.bio
- HQ
- South San Francisco, California
Leapfrog Bio Questions
Leapfrog Bio's website is https://www.leapfrog.bio
Leapfrog Bio's LinkedIn profile is https://www.linkedin.com/company/leapfrog-bio
Leapfrog Bio has
10 employees.
View email and phone details for 10
employees at Leapfrog Bio.
Leapfrog Bio's industry is
Biotechnology Research
Leapfrog Bio's top competitors are
Jaya Biosciences Inc.,
Two Bear Capital,
Sagimet Biosciences,
M6p Therapeutics,
Repare Therapeutics,
35pharma,
Prellis Biologics,
Inside Precision Medicine,
Caledon Bioscience Inc.,
Flare Therapeutics.
Leapfrog Bio's categories are Biotechnology Research
Leapfrog Bio's founding year is 2019
